Home merck announces
 

Keywords :   


Tag: merck announces

Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO (tedizolid phosphate)

2015-01-26 14:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO (tedizolid phosphate) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Merck acquired SIVEXTRO as a part of its purchase, through a subsidiary, of Cubist Pharmaceuticals, Inc. Language: English Contact: Media:Pam Eisele, 267-305-3558Jennifer Baird, 781-860-1282orInvestor:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: issues positive opinion announces

 

Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubists 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020

2015-01-22 21:29:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the acquisition of Cubist by Merck, Cubist has commenced a tender offer (the Convertible Notes Tender Offer) to repurchase, at the option of each holder, any and all of its outstanding 2.50% Convertible Senior Notes due 2017 (the 2017 Convertible Notes), 1.125% Convertible Senior Notes due 2018 (the

Tags: due offer notes senior

 
 

Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health

2014-12-10 15:30:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Dr. Julie Gerberding, 59, as executive vice president for strategic communications, global public policy and population health, effective Dec. 15. Language: English Contact: MerckMedia:Steven Cragle, 908-740-1801Lainie Keller, 908-236-5036orInvestors:Joe Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: policy public health global

 

Merck Announces Increased Quarterly Dividend

2014-11-25 19:00:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the companys quarterly dividend to $0.45 per outstanding share of the companys common stock, up $0.01 from $0.44 per outstanding share paid last quarter. Payment will be made on Jan. 8, 2015, to stockholders of record at the close of business on Dec. 15, 2014. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: increased quarterly announces dividend

 

Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today

2014-11-17 14:30:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. Data are Embargoed by American Heart Association until 10:45 AM CT Today WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today. About Merck Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data today american primary

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »